Real-world efficacy of fimasartan vs. other angiotensin receptor blockers in combination with calcium channel blockers: a nationwide cohort study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The antihypertensive efficacy of fimasartan was assessed based on the transition rate from a combination of calcium channel blockers (CCB) and angiotensin receptor blockers (ARB) to three-drug combination therapy, as compared to other ARBs.This nationwide cohort study used data obtained from the Korean National Health Insurance Service database. Patients who had received national health checkups within 2 years prior to January 1, 2017, and were concurrently prescribed ARBs and CCBs for > 30 days during the 6 months from January 1, 2017, to June 30, 2017 were included in the study. Patients were categorized into the ‘fimasartan group’ (those prescribed fimasartan) and the ‘non-fimasartan group’ (those prescribed ARBs other than fimasartan). The index date was set as the last day of a 30-day prescription period for ARBs and CCBs, with a subsequent 2.5-year follow-up to observe the potential addition of a third drug, such as beta-blockers or diuretics. The study included 34,422 patients with a mean age of 60.3 years and 58.3% being male. The fimasartan group constituted 2.7% ( n = 928) of the total, and the non-fimasartan group, 97.3% ( n = 33,494). During the follow-up period, 38 patients in the fimasartan group (14.3 per 1,000 person-years) and 3,557 patients in the non-fimasartan group (42.8 per 1,000 person-years) required additional antihypertensive medications. After multivariate adjustment for age, sex, diabetes mellitus, dyslipidemia, cancer, heart failure, systolic blood pressure, and diastolic blood pressure, the fimasartan group showed a significantly lower rate of adding a third medication (hazard ratio 2.68, 95% confidence interval 1.95–3.69) compared to that of the non-fimasartan group. Fimasartan is associated with a lower need for additional antihypertensive drugs compared to other ARBs. This implies its greater effectiveness in hypertension management, potentially enhancing cardiovascular outcomes, and minimizing polypharmacy.
Abstract
he antihypertensive efficacy of fimasartan was assessed based on the transition rate from a combination of calcium channel blockers (CCB) and angiotensin receptor blockers (ARB) to three-drug combination therapy, as compared to other ARBs.This nationwide cohort study used data obtained from the Korean National Health Insurance Service database. Patients who had received national health checkups within 2 years prior to January 1, 2017, and were concurrently prescribed ARBs and CCBs for > 30 days during the 6 months from January 1, 2017, to June 30, 2017 were included in the study. Patients were categorized into the ‘fimasartan group’ (those prescribed fimasartan) and the ‘non-fimasartan group’ (those prescribed ARBs other than fimasartan). The index date was set as the last day of a 30-day prescription period for ARBs and CCBs, with a subsequent 2.5-year follow-up to observe the potential addition of a third drug, such as beta-blockers or diuretics. The study included 34,422 patients with a mean age of 60.3 years and 58.3% being male. The fimasartan group constituted 2.7% ( n = 928) of the total, and the non-fimasartan group, 97.3% ( n = 33,494). During the follow-up period, 38 patients in the fimasartan group (14.3 per 1,000 person-years) and 3,557 patients in the non-fimasartan group (42.8 per 1,000 person-years) required additional antihypertensive medications. After multivariate adjustment for age, sex, diabetes mellitus, dyslipidemia, cancer, heart failure, systolic blood pressure, and diastolic blood pressure, the fimasartan group showed a significantly lower rate of adding a third medication (hazard ratio 2.68, 95% confidence interval 1.95–3.69) compared to that of the non-fimasartan group. Fimasartan is associated with a lower need for additional antihypertensive drugs compared to other ARBs. This implies its greater effectiveness in hypertension management, potentially enhancing cardiovascular outcomes, and minimizing polypharmacy.
참고문헌 (38)
- "Worldwide trends in. Hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants", Lancet, 398, pp.957~980 (2021)
- Zhou B, "Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension", Nat Rev Cardiol, 18, pp.785~802 (2021)
- Fuchs FD, "High blood pressure and Cardiovascular Disease", Hypertension, 75, pp.285~292 (2020)
- Chobanian AV, "Blood I and National High Blood Pressure Education Program Coordinating C. Seventh report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure", Hypertension, 42, pp.1206~1252 (2003)
- Neal B, "Effects of ACE inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists’ collaboration", Lancet, 356, pp.1955~1964 (2000)
- Psaty BM, "Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis", JAMA, 277, pp.739~745 (1997)
- Chow CK, "Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries", JAMA, 310, pp.959~968 (2013)
- Neutel JM, "Improving patient compliance : a major goal in the management of hypertension", J Clin Hypertens(Greenwich), 5, pp.127~132 (2003)
- Castellano JM, "A polypill strategy to improve adherence: results from the FOCUS project", J Am Coll Cardiol, 64, pp.2071~2082 (2014)
- Abraham HM, "The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases", Drug Saf, 38, pp.33~54 (2015)
- Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
- Williams B, "2018 ESC", ESH guidelines for the management of arterial hypertension, 2018, pp.39, 3021~3104
- Lee HY, "2018 Korean Society of Hypertension Guidelines for the management of hypertension : part II-diagnosis and treatment of hypertension", Clin Hypertens, 25, pp.20~ (2019)
- Kim TW, "Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1(AT1)antagonists", Bioorg Med Chem Lett, 22, pp.1649~1654 (2012)
- Chi YH, "Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects", Am J Cardiovasc Drugs, 11, pp.335~346 (2011)
- Lee H, "Ambulatory blood pressure response to once-daily fimasartan : an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension", Clin Ther, 35, pp.1337~1349 (2013)
- Oh H, "Blood pressure-lowering effect of Fimasartan Versus comparators : a cross-inference with a systematic review and Metaanalysis through a quality-management system", Clin Ther, 45, pp.437~455 (2023)
- Lee HY, "Fimasartan : a new angiotensin receptor blocker", Drugs, 76, pp.1015~1022 (2016)
- Kim HC, "Korea hypertension fact sheet 2022 : analysis of nationwide population-based data with a special focus on hypertension in the elderly", Clin Hypertens, 29, pp.22~ (2023)
- Choi YJ, "Augmented risk of ischemic stroke in hypertrophic cardiomyopathy patients without documented atrial fibrillation", Sci Rep, 12, pp.15785~ (2022)
- Park CS, "U-Shaped associations between Body Weight Changes and Major Cardiovascular events in type 2 diabetes Mellitus: a Longitudinal follow-up study of a Nationwide Cohort of Over 1.5 million", Diabetes Care, 45, pp.1239~1246 (2022)
- Park JB, "Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy", Eur J Prev Cardiol, 27, pp.1849~1857 (2020)
- Choi E-K, "Cardiovascular Research using the Korean National Health Information Database", Korean Circ J, 50, pp.754~772 (2020)
- Lee SR, "Hypertension Burden and the risk of New-Onset Atrial Fibrillation : a Nationwide Population-based study", Hypertension, 77, pp.919~928 (2021)
- Park CS, "Association between renin-angiotensin-aldosterone system blockade and clinical outcomes in patients with hypertension : real-world observation from a nationwide hypertension cohort", Clin Res Cardiol, 112, pp.1577~1586 (2023)
- Ferdinand KC, "Improving Medication Adherence in Cardiometabolic Disease : practical and Regulatory implications", J Am Coll Cardiol, 69, pp.437~451 (2017)
- Sabaté E, "Adherence to long-term therapies: evidence for action" (2003), World Health Organization
- Osterberg L, "Adherence to medication", N Engl J Med, 353, pp.487~497 (2005)
- Hill MN, "Adherence and persistence with taking medication to control high blood pressure", J Am Soc Hypertens, 5, pp.56~63 (2011)
- Burnier M, "Drug adherence in hypertension", Pharmacol Res, 125, pp.142~149 (2017)
- Masnoon N, "What is polypharmacy? A systematic review of definitions", BMC Geriatr, 17, pp.230~ (2017)
- Miura S, "Review : angiotensin II type 1 receptor blockers : class effects versus molecular effects", J Renin Angiotensin Aldosterone Syst, 12, pp.1~7 (2011)
- Zhang H, "Structure of the angiotensin receptor revealed by serial femtosecond crystallography", Cell, 161, pp.833~844 (2015)
- Lee SE, "Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan(50", 100 mg) : a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension, 2012, pp.34, 552~568
- Youn JC, "Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension : an 8-week, multicenter, randomized, double-blind, phase III clinical study", Clin Ther, 36, pp.1412~1421 (2014)
- Lee HY, "24-Hour blood pressure response to lower dose(30 mg)fimasartan in Korean patients with mild to moderate essential hypertension", Korean J Intern Med, 32, pp.1025~1036 (2017)
- Lee JH, "Double-blind, Candesartan-controlled, parallel Group Comparison Clinical Trial to evaluate the antihypertensive efficacy and safety of Fimasartan in patients with mild to moderate essential hypertension", Clin Ther, 38, pp.1485~1497 (2016)
- Chung WB, "Effect of Fimasartan versus Valsartan and Olmesartan on Office and ambulatory blood pressure in Korean patients with mild-to-moderate essential hypertension : a Randomized, Double-Blind, active control, Three-Parallel Group, forced Titration, Multicenter, Phase IV Study(Fimasartan Achieving Systolic blood pressure target(FAST)study)", Drug Des Devel Ther, 14, pp.347~360 (2020)